A 10-fold Sensitivity Jump, Broad-band Mass Resolution of >1,000,000 and Sub-ppm Mass Accuracy Make the solariX Ideal for the Analysis of Very Complex Mixtures in
Top-Down Proteomics (including ETD & ECD),
Petroleomics,
Metabolomics, and
Small-Molecule Drug and Metabolite MALDI Imaging
BILLERICA, Mass.--(BUSINESS WIRE)--May. 19, 2009--
Bruker Daltonicstoday launched thesolariX™, its next generation hybrid Qq-FTMS platform. ThesolariXis the culmination of a number of key technology developments that deliver unique capabilities and unparalleled ultra-high resolution mass spectrometry performance and versatility. At the core of these innovations are dramatically improved broad-band mass resolving power (8x over earlier platforms), sensitivity (> 10x over earlier platforms) and dynamic range. These dramatic improvements help address today’s most challenging top-down proteomics and complex mixture applications.
Its broad-band, ultra-high resolving power (> 1,000,000 @ m/z 400, for a 7 tesla instrument) and outstanding sub-ppm mass accuracy make thesolariXmore powerful than any previous mass spectrometer for the analysis of extremely complex mixtures. This extraordinary increase in the number of available m/z channels is essential for tackling very complex mixtures, especially those that are not amenable to high-resolution chromatography separation techniques. These applications can include: hydrocarbon related analysis (“petroleomics”), environmental soil/sediment analysis, small-molecule biological tissue MALDI imaging, metabolomics, and the inherently complex peak patterns resulting from top-down proteomics.
For applications that require high performance LC-FTMS or LC-MS/FTMS, thesolariXoffers faster and smart data-dependent acquisition capabilities. Moreover, sub-ppm mass accuracy is maintained throughout the LC-MS analysis using Bruker’s proprietary Ion Charge Control (ICC™) method.
Adding to the existing arsenal of top-down proteomics structural fragmentation tools (ECD, Q-CID, in-cell SORI-CID),solariXis now the first FTMS system with Electron Transfer Dissociation (ETD). This exciting new technique is superb for in-depth, comprehensive analysis of proteins and peptides and their labile, post-translational modifications (PTMs). ETD-analysis has been fully automated and can be combined with LC-MS/FTMS workflows in combination with quadrupole fragmentation (Q-CID) to provide unprecedented levels of protein structural information. ThesolariXcan also be easily incorporated into the workflows of other mainstream proteomics platforms such as the new
BrukerultrafleXtremeMALDI-TOF/TOF (for high throughput biomarker discovery/quantitation and Edmass™ protein sequencing) andamaZonion trap (for high-throughput LC-MS/MS). ThesolariXprovides complementary analytical capabilities through the combination of unique dissociation tools with the performance necessary to address the most challenging structural or functional proteomics applications, including protein structural studies and PTM characterization.
The new dual ion funnel source combined with a unique rf ion transfer system makes thesolariXFTMS as intuitive and easy to use as a benchtop ion trap mass spectrometer. Operation of the instrument is performed using Bruker’s unifiedCompass™software, enabling researchers to harness the analytical power and versatility of FTMS with ease.
ThesolariXcan be configured with a unique dual ESI/MALDI source, and a range of API source options (APCI, GC-APCI, APPI). Low maintenance, refrigerated magnets are standard at several magnetic field options, including 7T, 9.4T, 12T and 15T. ThesolariXis the realization of the highest performance FTMS product ever released to the marketplace, equally well suited for small molecule or protein applications.
教授André Deelder (
Leiden University Medical Center,
Netherlands) commented: “Part of our mission is to leverage new, enabling technologies for life science research. Therefore, we are very excited to have received the first twosolariXsystems, which are 12 tesla and 15 tesla instruments. The advanced performance and added capabilities ofsolariXhave been integrated into our proteomics and metabolomics workflows. They will increase our capacity for in-depth characterization and quantitative analysis of the large number of samples generally encountered in clinical studies, and will enable us to identify more proteins with very high quantitative precision.”
教授
Michael Gross(
Washington University,
St. Louis, MO) stated: “Our work in top-down protein characterization will greatly benefit from the enhanced sensitivity and ETD capabilities of thesolariXFTMS. We have purchased thesolariX12T system and are very much looking forward to having it in our laboratory.”
ThesolariXwill be highlighted at
Bruker'sAnnual Users Meeting on
Sunday, May 31st2009前57th
ASMS Conference on Mass Spectrometryin
Philadelphia, PA.For more information on this event, please visitwww.bdal.com/asms2009. For further product information, please visitwww.bdal.com/solariX.
ABOUT
BRUKER DALTONICS:For more information about
Bruker Daltonics
and Bruker Corporation(NASDAQ: BRKR), please visitwww.bdal.comandwww.fatactor.com.
Photos/Multimedia Gallery Available:http://www.businesswire.com/cgi-bin/mmg。cgi?eid=5968412&lang=en
Source:
Bruker Daltonics
Bruker Daltonics
Darwin Asa, Ph.D., +1 978-663-3660, ext. 1149
Life-Science Marketing Manager
dja@bdal.com